The FDA has approved lenacapvir, a twice-yearly injection to prevent HIV infection that could improve adherence rates compared to other PrEP medications. The drug, which will be sold under the brand ...
Arrivals of the twice-yearly PrEP option in Eswatini and Zambia mark an important milestone in the goal of ending the HIV epidemic in sub-Saharan Africa “The arrivals of the first doses of lenacapavir ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback